Phase I clinical trial - Sein métastatique triple négatif

CO40151
Sein métastatique triple négatif
Ouvert depuis le: 10.22.2020
Site: Paris
Public cible
Adulte
A phase ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel in patients with locally advanced or metastatic triple- negative breast cancer
Description de l'essai

This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel as a first-line treatment in patients with locally advanced or metastatic triple negative breast cancer.